0113 IO Biotech
BioCentury & Getty Images


With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

Jan 14, 2021 | 2:05 AM GMT

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support

Read the full 538 word article

How to gain access

Continue reading with a
two-week free trial.